{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ebe8cc563e3d811bbd2c9d8/6141b2252527ca00124504d5?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Does 'cure' have a different meaning in MM?","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5ebe8cc563e3d811bbd2c9d8/1589546617002-fe8127d1b39ab8ac94a64885bbfaa0ae.jpeg?height=200","description":"<p>During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should '<em>cure</em>' be the goal for multiple myeloma? Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR, answered: Does 'cure' have a different meaning in MM?</p><p><br></p><p>In this podcast, Mohty discusses how the word 'cure' has different implications for young and older patients, and discusses the functional/operational cure for patients with standard- and high-risk disease. Mohty focuses on the importance of sustained MRD negativity on survival and why it should also be monitored by PET-CT. Seeing novel agent combinations reaching unprecedented results, he is hopeful that the cure rates will rise in both young and older patients with MM in the near future.</p>","author_name":"Scientific Education Support"}